Holen Sie sich die Stockscreener-App
17.04
1.33%
-0.23
Handel nachbörslich:
17.25
0.21
+1.23%
Schlusskurs vom Vortag:
$17.27
Offen:
$17.26
24-Stunden-Volumen:
2.01M
Relative Volume:
0.71
Marktkapitalisierung:
$12.69B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-746.08M
KGV:
-16.91
EPS:
-1.0074
Netto-Cashflow:
$-211.81M
1W Leistung:
-13.41%
1M Leistung:
-1.10%
6M Leistung:
-39.72%
1J Leistung:
-6.32%
1-Tages-Spanne:
$17.02
$17.48
1-Wochen-Bereich:
$16.27
$19.90
52-Wochen-Spanne:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.04 | 12.86B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
(SMMT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Buyout Rumor: Will Summit Therapeutics Inc outperform the market in YEAR2025 Major Catalysts & Long-Term Growth Stock Strategies - baoquankhu1.vn
Assessing Summit Therapeutics (SMMT) Valuation After Ivonescimab FDA Filing And New GSK Trial Collaboration - Sahm
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Summit Therapeutics PLC $SMMT Shares Purchased by APEIRON CAPITAL Ltd - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Nasdaq 100 Index Biotech Position - Kalkine Media
Summit Therapeutics stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Can Summit Therapeutics Inc. be the next market leaderBull Market Opportunities & Breakout Portfolio Performance - bollywoodhelpline.com
Rate Cut: Will Summit Therapeutics Inc benefit from AI trends2025 Macro Impact & Weekly Return Optimization Alerts - baoquankhu1.vn
Is Summit Therapeutics (SMMT) Still Attractive After Recent Pullback And Multi Year Surge - Yahoo Finance
Citizens reiterates Market Outperform rating on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics (SMMT) Is Down 8.7% After Ivonescimab BLA Filing And Oncology Expansion Update – Has The Bull Case Changed? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 13.4%What's Next? - MarketBeat
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows - TechStock²
2 Biotech Stocks That Could Soar This Year - The Globe and Mail
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC - Business Wire
GSK Collaborates with Summit Therapeutics on Cancer Treatment Tr - GuruFocus
Summit Therapeutics Files Marketing Application for Lung Cancer Therapy - 富途牛牛
Summit Therapeutics (SMMT) Seeks FDA Approval for Innovative Lun - GuruFocus
Summit Therapeutics partners with GSK for cancer drug combination trial - StreetInsider
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) - FinancialContent
Summit Therapeutics files FDA application for cancer drug ivonescimab - StreetInsider
Summit Therapeutics Inc. (SMMT): Investor Outlook on a Biotech Stock with 66.79% Upside Potential - DirectorsTalk Interviews
Summit Therapeutics (SMMT) Grants Stock Options to New Employees - GuruFocus
Cantor Fitzgerald reaffirms overweight rating on Summit Therapeutics (SMMT) before key 2026 catalyst - MSN
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Summit Therapeutics gives 17 new hires options on 214,331 shares - Stock Titan
How Summit Therapeutics Inc. stock valuations compare to rivalsJuly 2025 Technicals & Free Community Supported Trade Ideas - ulpravda.ru
Can Summit Therapeutics Inc. stock continue upward trendPrice Action Trading & Accelerated Earnings Growth - ulpravda.ru
A Look At Summit Therapeutics (SMMT) Valuation After Recent Share Price Strength - Yahoo Finance
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - The Motley Fool
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Price-Driven Insight from (SMMT) for Rule-Based Strategy - Stock Traders Daily
Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst - Finviz
Summit Therapeutics Earnings Notes - Trefis
15 Best Stocks Under $25 to Buy Now - Insider Monkey
Farther Finance Advisors LLC Makes New $1.14 Million Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Capricorn Fund Managers Ltd Takes $10.25 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Closing the Year With Gratitude and Shared Purpose – Summit Therapeutics - Oncodaily
Summit Therapeutics Inc. (SMMT) Stock Analysis: An 83.78% Potential Upside In Biotech - DirectorsTalk Interviews
Summit Therapeutics Shares Slip Following Mixed Results from Lung Cancer Trial - MSN
Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Summit Therapeutics Inc. stock a defensive play in 20252025 Price Momentum & Free Community Consensus Stock Picks - Улправда
How Summit Therapeutics Inc. stock compares to industry benchmarks2025 Big Picture & Long Hold Capital Preservation Plans - ulpravda.ru
Will Summit Therapeutics Inc. stock outperform Dow Jones indexPortfolio Return Report & AI Powered Buy and Sell Recommendations - ulpravda.ru
Summit Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Gap Down: How Summit Therapeutics Inc. stock valuations compare to rivalsWeekly Market Summary & Low Risk Profit Maximizing Plans - DonanımHaber
Gains Recap: Will Summit Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 WrapUp & Weekly Stock Breakout Alerts - Улправда
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.73%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):